NFKB1 and pancreatic neoplasm: In pancreatic tumors, gemcitabine targets the knockdown of the p65 subunit in the NF‐kB pathway, thereby causing immune suppression and abrogation of cell proliferation as the combined result of the different anticancer modalities of gemcitabine.